Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
Identifieur interne : 004653 ( Main/Exploration ); précédent : 004652; suivant : 004654Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
Auteurs : James C. Coons [États-Unis] ; Taylor Miller [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2014-09.
Descripteurs français
- KwdFr :
- Antiagrégants plaquettaires (administration et posologie), Antiagrégants plaquettaires (effets indésirables), Antiagrégants plaquettaires (usage thérapeutique), Anticoagulants (administration et posologie), Anticoagulants (effets indésirables), Anticoagulants (usage thérapeutique), Humains, Hémorragie (), Intervention coronarienne percutanée (), Relation dose-effet des médicaments, Surveillance pharmacologique (), Syndrome coronarien aigu ().
- MESH :
- administration et posologie : Antiagrégants plaquettaires, Anticoagulants.
- effets indésirables : Antiagrégants plaquettaires, Anticoagulants.
- usage thérapeutique : Antiagrégants plaquettaires, Anticoagulants.
- Humains, Hémorragie, Intervention coronarienne percutanée, Relation dose-effet des médicaments, Surveillance pharmacologique, Syndrome coronarien aigu.
English descriptors
- KwdEn :
- Acute Coronary Syndrome (therapy), Anticoagulants (administration & dosage), Anticoagulants (adverse effects), Anticoagulants (therapeutic use), Dose-Response Relationship, Drug, Drug Monitoring (methods), Hemorrhage (chemically induced), Hemorrhage (prevention & control), Humans, Percutaneous Coronary Intervention (methods), Platelet Aggregation Inhibitors (administration & dosage), Platelet Aggregation Inhibitors (adverse effects), Platelet Aggregation Inhibitors (therapeutic use).
- MESH :
- chemical , administration & dosage : Anticoagulants, Platelet Aggregation Inhibitors.
- chemical , adverse effects : Anticoagulants, Platelet Aggregation Inhibitors.
- chemical , therapeutic use : Anticoagulants, Platelet Aggregation Inhibitors.
- chemically induced : Hemorrhage.
- methods : Drug Monitoring, Percutaneous Coronary Intervention.
- prevention & control : Hemorrhage.
- therapy : Acute Coronary Syndrome.
- Dose-Response Relationship, Drug, Humans.
Abstract
Bleeding is a well‐recognized complication among patients who undergo percutaneous coronary intervention for acute coronary syndromes. Patients who bleed in this setting have higher morbidity, mortality, and resource use. Several bleeding avoidance strategies have been identified including the use of certain pharmacologic interventions; however, the antithrombotic landscape for this patient population is evolving rapidly. Numerous practical issues are related to the appropriate selection and dosing of antiplatelets and anticoagulants, as well as their combinations, that may have an impact on bleeding. Thus we reviewed the recent evidence that describes the use of these agents and provide recommendations on the appropriate use of antiplatelets and anticoagulants in the context of current practice and guideline recommendations. Opportunities exist to reduce bleeding complications through the adoption of bleeding avoidance strategies and appropriate use of antiplatelets and anticoagulants. Pharmacist expertise is critical in the appropriate selection, dosing, and monitoring of these medications to improve patient safety as it relates to bleeding potential. Clinical outcomes evaluating combinations of antiplatelets and anticoagulants, particularly with novel anticoagulants, are ongoing as are studies that incorporate use of genotype and phenotype into antithrombotic decision making.
Url:
DOI: 10.1002/phar.1447
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E49
- to stream Istex, to step Curation: 000E49
- to stream Istex, to step Checkpoint: 000157
- to stream PubMed, to step Corpus: 001E46
- to stream PubMed, to step Curation: 001E37
- to stream PubMed, to step Checkpoint: 001E37
- to stream Ncbi, to step Merge: 002371
- to stream Ncbi, to step Curation: 002371
- to stream Ncbi, to step Checkpoint: 002371
- to stream Main, to step Merge: 004885
- to stream Main, to step Curation: 004653
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations</title><author><name sortKey="Coons, James C" sort="Coons, James C" uniqKey="Coons J" first="James C." last="Coons">James C. Coons</name></author><author><name sortKey="Miller, Taylor" sort="Miller, Taylor" uniqKey="Miller T" first="Taylor" last="Miller">Taylor Miller</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3CC37F3A895C36DD4B7EC762E403B21C315246D0</idno><date when="2014" year="2014">2014</date><idno type="doi">10.1002/phar.1447</idno><idno type="url">https://api.istex.fr/document/3CC37F3A895C36DD4B7EC762E403B21C315246D0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E49</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E49</idno><idno type="wicri:Area/Istex/Curation">000E49</idno><idno type="wicri:Area/Istex/Checkpoint">000157</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000157</idno><idno type="wicri:doubleKey">0277-0008:2014:Coons J:strategies:to:reduce</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:24898316</idno><idno type="wicri:Area/PubMed/Corpus">001E46</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E46</idno><idno type="wicri:Area/PubMed/Curation">001E37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E37</idno><idno type="wicri:Area/PubMed/Checkpoint">001E37</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E37</idno><idno type="wicri:Area/Ncbi/Merge">002371</idno><idno type="wicri:Area/Ncbi/Curation">002371</idno><idno type="wicri:Area/Ncbi/Checkpoint">002371</idno><idno type="wicri:Area/Main/Merge">004885</idno><idno type="wicri:Area/Main/Curation">004653</idno><idno type="wicri:Area/Main/Exploration">004653</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations</title><author><name sortKey="Coons, James C" sort="Coons, James C" uniqKey="Coons J" first="James C." last="Coons">James C. Coons</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>University of Pittsburgh School of Pharmacy, Pennsylvania</wicri:orgArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Miller, Taylor" sort="Miller, Taylor" uniqKey="Miller T" first="Taylor" last="Miller">Taylor Miller</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>Department of Pharmacy, UPMC‐Presbyterian Hospital, Pennsylvania</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><title level="j" type="alt">PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><biblScope unit="vol">34</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="973">973</biblScope><biblScope unit="page" to="990">990</biblScope><biblScope unit="page-count">18</biblScope><date type="published" when="2014-09">2014-09</date></imprint><idno type="ISSN">0277-0008</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Coronary Syndrome (therapy)</term><term>Anticoagulants (administration & dosage)</term><term>Anticoagulants (adverse effects)</term><term>Anticoagulants (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Monitoring (methods)</term><term>Hemorrhage (chemically induced)</term><term>Hemorrhage (prevention & control)</term><term>Humans</term><term>Percutaneous Coronary Intervention (methods)</term><term>Platelet Aggregation Inhibitors (administration & dosage)</term><term>Platelet Aggregation Inhibitors (adverse effects)</term><term>Platelet Aggregation Inhibitors (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiagrégants plaquettaires (administration et posologie)</term><term>Antiagrégants plaquettaires (effets indésirables)</term><term>Antiagrégants plaquettaires (usage thérapeutique)</term><term>Anticoagulants (administration et posologie)</term><term>Anticoagulants (effets indésirables)</term><term>Anticoagulants (usage thérapeutique)</term><term>Humains</term><term>Hémorragie ()</term><term>Intervention coronarienne percutanée ()</term><term>Relation dose-effet des médicaments</term><term>Surveillance pharmacologique ()</term><term>Syndrome coronarien aigu ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term><term>Platelet Aggregation Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term><term>Platelet Aggregation Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term><term>Platelet Aggregation Inhibitors</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiagrégants plaquettaires</term><term>Anticoagulants</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiagrégants plaquettaires</term><term>Anticoagulants</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term><term>Percutaneous Coronary Intervention</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiagrégants plaquettaires</term><term>Anticoagulants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Hémorragie</term><term>Intervention coronarienne percutanée</term><term>Relation dose-effet des médicaments</term><term>Surveillance pharmacologique</term><term>Syndrome coronarien aigu</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Bleeding is a well‐recognized complication among patients who undergo percutaneous coronary intervention for acute coronary syndromes. Patients who bleed in this setting have higher morbidity, mortality, and resource use. Several bleeding avoidance strategies have been identified including the use of certain pharmacologic interventions; however, the antithrombotic landscape for this patient population is evolving rapidly. Numerous practical issues are related to the appropriate selection and dosing of antiplatelets and anticoagulants, as well as their combinations, that may have an impact on bleeding. Thus we reviewed the recent evidence that describes the use of these agents and provide recommendations on the appropriate use of antiplatelets and anticoagulants in the context of current practice and guideline recommendations. Opportunities exist to reduce bleeding complications through the adoption of bleeding avoidance strategies and appropriate use of antiplatelets and anticoagulants. Pharmacist expertise is critical in the appropriate selection, dosing, and monitoring of these medications to improve patient safety as it relates to bleeding potential. Clinical outcomes evaluating combinations of antiplatelets and anticoagulants, particularly with novel anticoagulants, are ongoing as are studies that incorporate use of genotype and phenotype into antithrombotic decision making.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region><settlement><li>Pittsburgh</li></settlement></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Coons, James C" sort="Coons, James C" uniqKey="Coons J" first="James C." last="Coons">James C. Coons</name></region><name sortKey="Coons, James C" sort="Coons, James C" uniqKey="Coons J" first="James C." last="Coons">James C. Coons</name><name sortKey="Miller, Taylor" sort="Miller, Taylor" uniqKey="Miller T" first="Taylor" last="Miller">Taylor Miller</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004653 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004653 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3CC37F3A895C36DD4B7EC762E403B21C315246D0
|texte= Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
}}
| This area was generated with Dilib version V0.6.38. |  |